Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients with Cirrhosis

This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced ultrasound imaging, may help find and diagnose liver cancer.
Not Available
Not Available
Planz, Virginia
Vanderbilt University


21 Years
Inclusion Criteria:

Capable of making informed decisions regarding his/her treatment

Have known cirrhosis or other risk factors for HCC, based on American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines (applicable in each site jurisdictions)

Patients with untreated focal liver observations on liver ultrasound or multiphase contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) performed as part of clinical standard of care within 4 weeks before patient enrollment

Patients with untreated focal liver observations scheduled for follow-up multiphase contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of care; CEUS should be performed within 4 weeks before or after follow-up imaging or within 4 weeks before biopsy or surgical excision

Exclusion Criteria:

Patients who are pregnant or lactating

Patients with focal liver observations less than 5 mm or greater than 5 cm in size

Patients with contraindications to CEUS

Patients with contraindications to both CT and MRI

Patients who are medically unstable, terminally ill, or whose clinical course is unpredictable

Liver nodule previously treated with trans-arterial or thermal ablation

Patients who have received an investigational drug in the 30 days before CEUS, or will receive one within 72 hour after their CEUS exam

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: